Bryan, Garnier & Co recently hosted a special “Oncology Day” with the Institute Curie in Paris. Attended by leading experts in cancer research and treatment as well as strategic investors and fund managers, the subject of immune-oncology was discussed in detail.
The growing importance of biological and immunology therapies is
expected to drive the global market for immuno-oncology drugs to over $30
billion by 2020. To help investors understand the key trends, we have captured
these insights in a new report.